Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
utidelone + toripalimab
- Development stage
- Unknown
- Lead developer
- Biostar Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
utidelone + toripalimab is a combination therapy consisting of utidelone, a genetically engineered epothilone derivative, and toripalimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Utidelone acts as a microtubule-stabilizing agent, inducing cell cycle arrest and apoptosis by binding to tubulin, while toripalimab functions as a checkpoint inhibitor that restores T-cell mediated anti-tumor immune responses. This combination is being evaluated in clinical trials, such as the Phase II study led by Zhongnan Hospital, for the treatment of pretreated recurrent or metastatic cervical cancer, aiming to leverage the synergistic effects of cytotoxic chemotherapy and immunotherapy.
- Brand names
- Youdi'anTuoyi
- Other names
- utidelone plus toripalimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on utidelone + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on utidelone + toripalimab.